Trypanocidal drugs: Mechanisms, resistance and new targets

Expert Reviews in Molecular Medicine

Volumn 11, Issue , 2009, Pages

  Wilkinson, Shane R ^a   Kelly, John M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; NITROFURAN DERIVATIVE; NITROREDUCTASE; PROTOZOAL PROTEIN;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PARASITOLOGY; REVIEW; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

CHAGAS DISEASE; HUMANS; NITROFURANS; NITROREDUCTASES; PROTOZOAN PROTEINS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 78751534394     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409001252     Document Type: Review

References (253)

1. Steverding, D. (2008) The history of African trypanosomiasis. Parasites and Vectors 1, 3
2. Barrett, M.P. et al. (2003) The trypanosomiases. Lancet 362, 1469-1480 (Pubitemid 37352887)
3. Stuart, K. et al. (2008) Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation 118, 1301-1310 (Pubitemid 351500422)
4. Barrett, M.P. (2006) The rise and fall of sleeping sickness. Lancet 367, 1377-1378
5. Matovu, E. et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Molecular and Biochemical Parasitology 117, 73-81 (Pubitemid 32823484)
6. Checchi, F. et al. (2007) Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Neglected Tropical Diseases 1, e64
7. Priotto, G. et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clinical Trials 1, e39
8. Priotto, G. et al. (2009) Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374, 56-64
9. Docampo, R. and Moreno, S.N. (2003) Current chemotherapy of human African trypanosomiasis. Parasitology Research 90, S10-13 (Pubitemid 36831288)
10. Nok, A.J. (2003) Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitology Research 90, 71-79
11. Legros, D. et al. (2002) Treatment of human African trypanosomiasis- present situation and needs for research and development. Lancet Infectious Diseases 2, 437-440 (Pubitemid 34693262)
12. Spinks, A. (1948) The persistence in the blood stream of some compounds related to suramin. Biochemical Journal 42, 109-116
13. Fairlamb, A.H. and Bowman, I.B. (1980) Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. Molecular and Biochemical Parasitology 1, 315-333
14. Coppens, I. et al. (1987) Receptor-mediated endocytosis in the bloodstream form of Trypanosoma brucei. Journal of Protozoology 34, 465-473
15. Vansterkenburg, E.L. et al. (1993) The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Tropica 54, 237-250 (Pubitemid 23306687)
16. Pal, A., Hall, B.S. and Field, M.C. (2002) Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. Molecular and Biochemical Parasitology 122, 217-221 (Pubitemid 34775091)
17. Scott, A.G., Tait, A. and Turner, C.M. (1996) Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin. Acta Tropica 60, 251-262 (Pubitemid 26103147)
18. Mutugi, M.W., Boid, R. and Luckins, A.G. (1994) Experimental induction of suramin-resistance in cloned and uncloned stocks of Trypanosoma evansi using immunosuppressed and immunocompetent mice. Tropical Medicine and Parasitology 45, 232-236 (Pubitemid 24312031)
19. Misset, O. and Opperdoes, F.R. (1987) The phosphoglyceratekinases fromTrypanosomabrucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin. European Journal of Biochemistry 162, 493-500 (Pubitemid 17023100)
20. Willson, M. et al. (1993) Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Molecular and Biochemical Parasitology 59, 201-210
21. Conte, J.E., Jr, Upton, R.A. and Lin, E.T. (1987) Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. Journal of Infectious Diseases 156, 885-890 (Pubitemid 18017063)
22. Berger, B.J. et al. (1992) Primary and secondary metabolism of pentamidine by rats. Antimicrobial Agents and Chemotherapy 36, 1825-1831
23. Berger, B.J. and Fairlamb, A.H. (1993) Cytochrome P450 in trypanosomatids. Biochemical Pharmacology 46, 149-157 (Pubitemid 23218593)
24. Sanderson, L. et al. (2009) Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. Journal of Pharmacology and Experimental Therapeutics 329, 967-977
25. Carter, N.S., Berger, B.J. and Fairlamb, A.H. (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Journal of Biological Chemistry 270, 28153-28157
26. de Koning, H.P., and Jarvis, S.M. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Tropica 80, 245-250
27. Berger, B.J., Carter, N.S. and Fairlamb, A.H. (1995) Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 69, 289-298
28. Matovu, E. et al. (2003) Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryotic Cell 2, 1003-1008 (Pubitemid 37298713)
29. De Koning, H.P. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Molecular Pharmacology 59, 586-592
30. Bridges, D.J. et al. (2007) Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Molecular Pharmacology 71, 1098-1108 (Pubitemid 46457013)
31. Wilson,W.D. et al. (2008) Antiparasitic compounds that target DNA. Biochimie 90, 999-1014
32. Mathis, A.M. et al. (2006) Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrobial Agents and Chemotherapy 50, 2185-2191 (Pubitemid 43807541)
33. Shapiro, T.A. and Englund, P.T. (1990) Selective cleavage of kinetoplastDNAminicircles promoted by antitrypanosomal drugs. Proceedings of the National Academy of Sciences of the United States of America 87, 950-954
34. Wang, C.C. (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annual Review of Pharmacology and Toxicology 35, 93-127
35. Bitonti, A.J., Dumont, J.A. and McCann, P.P. (1986) Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochemical Journal 237, 685-689 (Pubitemid 16003770)
36. Benaim, G. et al. (1993) A calmodulinstimulated Ca2+ pump in plasma-membrane vesicles from Trypanosoma brucei; selective inhibition by pentamidine. Biochemical Journal 296, 759-763
37. Vercesi, A.E. and Docampo, R. (1992) Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochemical Journal 284, 463-467
38. Moreno, S.N. (1996) Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Archives of Biochemistry and Biophysics 326, 15-20
39. Friedheim, E.A. (1949) Mel B in the treatment of human trypanosomiasis. American Journal of Tropical Medicine and Hygiene 29, 173-180
40. Enanga, B. et al. (2002) Sleeping sickness and the brain. Cellular and Molecular Life Sciences 59, 845-858 (Pubitemid 34628245)
41. Blum, J. and Burri, C. (2002) Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Medical Weekly 132, 51-56 (Pubitemid 34311005)
42. Burri, C. et al. (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39, 225-234 (Pubitemid 23198849)
43. Carter, N.S. and Fairlamb, A.H. (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361, 173-176 (Pubitemid 23031354)
44. Maser, P. et al. (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285, 242-244 (Pubitemid 29329994)
45. Barrett, M.P. and Fairlamb, A.H. (1999) The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitology Today 15, 136-140 (Pubitemid 29222699)
46. Tye, C.K. et al. (1998) An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorganic and Medicinal Chemistry Letters 8, 811-816
47. de Koning, H.P. and Jarvis, S.M. (1999) Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs. Molecular Pharmacology 56, 1162-1170
48. de Koning, H.P. (2001) Transporters in African trypanosomes: role in drug action and resistance. International Journal of Parasitology 31, 512-522
49. Baliani, A. et al. (2005) Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. Journal of Medicinal Chemistry 48, 5570-5579 (Pubitemid 41209254)
50. Stewart, M.L. et al. (2004) Trypanocidal activity of melamine-based nitroheterocycles. Antimicrobial Agents and Chemotherapy 48, 1733-1738 (Pubitemid 38544382)
51. Baliani, A. et al. (2009) Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites. Organic and Biomolecular Chemistry 7, 1154-1166
52. Chollet, C. et al. (2009) Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. Bioorganic and Medicinal Chemistry 17, 2512-2523
53. Fairlamb, A.H. et al. (1992) Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Molecular and Biochemical Parasitology 53, 213-222 54 de Koning, H.P. (2008) Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends in Parasitology 24, 345-349
54. Van Schaftingen, E., Opperdoes, F.R. and Hers, H.G. (1987) Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei. European Journal of Biochemistry 166, 653-661
55. Hanau, S. et al. (1996) 6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs. European Journal of Biochemistry 240, 592-599 (Pubitemid 26321160)
56. Fairlamb, A.H. et al. (1985) Trypanothione: a novel bis(glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 1485-1487 (Pubitemid 15146992)
57. Fairlamb, A.H., Henderson, G.B. and Cerami, A. (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 86, 2607-2611 (Pubitemid 19112596)
58. Cunningham, M.L., Zvelebil, M.J. and Fairlamb, A.H. (1994) Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. European Journal of Biochemistry 221, 285-295 (Pubitemid 24120573)
59. Krieger, S. et al. (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Molecular Microbiology 35, 542-552 (Pubitemid 30085272)
60. Sauvage, V. et al. The role of ATP-Binding Cassette (ABC) proteins in protozoan parasites. Molecular and Biochemical Parasitology 167, 81-94
61. Shahi, S.K., Krauth-Siegel, R.L. and Clayton, C.E. (2002) Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Molecular Microbiology 43, 1129-1138 (Pubitemid 34304532)
62. Alibu, V.P. et al. (2006) The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Molecular and Biochemical Parasitology 146, 38-44 (Pubitemid 43132801)
63. Bacchi, C.J. et al. (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210, 332-334 (Pubitemid 11208468)
64. Robays, J. et al. (2008) Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. Tropical Medicine and International Health 13, 265-271 (Pubitemid 351316979)
65. Sanderson, L. et al. (2008) The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. Journal of Neurochemistry 107, 1136-1146
66. Balasegaram, M. et al. (2009) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Transactions of the Royal Society of Tropical Medicine and Hygiene 103, 280-290
67. Politi, C. et al. (1995) Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Health Eeconomics 4, 273-287
68. Chappuis, F. et al. (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clinical Infectious Diseases 41, 748-751 (Pubitemid 41170365)
69. Bellofatto, V. et al. (1987) Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Molecular and Biochemical Parasitology 25, 227-238
70. Erwin, B.G. and Pegg, A.E. (1982) Uptake of alpha-difluoromethylornithine by mouse fibroblasts. Biochemical Pharmacology 31, 2820-2823
71. Bitonti, A.J. et al. (1986) Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochemical Pharmacology 35, 351-354
72. Phillips, M.A. and Wang, C.C. (1987) A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Molecular and Biochemical Parasitology 22, 9-17 (Pubitemid 17225810)
73. Willert, E.K. and Phillips, M.A. (2008) Regulated expression of an essential allosteric activator of polyamine biosynthesis in African trypanosomes. PLoS Pathogens 4, e1000183
74. Phillips, M.A., Coffino, P. and Wang, C.C. (1987) Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. Journal of Biological Chemistry 262, 8721-8727 (Pubitemid 17102675)
75. Ghoda, L. et al. (1990) Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. Journal of Biological Chemistry 265, 11823-11826 (Pubitemid 20219354)
76. Tabor, C.W. and Tabor, H. (1984) Polyamines. Annual Review of Biochemistry 53, 749-790 (Pubitemid 14059150)
77. Iten, M. et al. (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrobial Agents and Chemotherapy 41, 1922-1925 (Pubitemid 27383228)
78. Schofield, C.J., Jannin, J. and Salvatella, R. (2006) The future of Chagas disease control. Trends in Parasitology 22, 583-588 (Pubitemid 44781088)
79. Bern, C. et al. (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. Journal of the American Medical Association 298, 2171-2181 (Pubitemid 350106656)
80. Diazgranados, C.A. et al. (2009) Chagasic encephalitis in HIVpatients: commonpresentation of an evolving epidemiological and clinical association. Lancet Infectious Diseases 9, 324-330
81. Dias, J.C., Silveira, A.C. and Schofield, C.J. (2002) The impact of Chagas disease control in Latin America: a review. Memorias do Instituto Oswaldo Cruz 97, 603-612 (Pubitemid 135746072)
82. Rodriques Coura, J. and de Castro, S.L. (2002) A critical review on Chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz 97, 3-24
83. Gorla, N.B. et al. (1989) Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutation Research 224, 263-267 (Pubitemid 19248960)
84. Ferreira, R.C., Schwarz, U. and Ferreira, L.C. (1988) Activation of anti-Trypanosoma cruzi drugs to genotoxic metabolites promoted by mammalian microsomal enzymes. Mutation Research 204, 577-583 (Pubitemid 18090224)
85. Kalil, J. and Cunha-Neto, E. (1996) Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last? Parasitology Today 12, 396-399 (Pubitemid 26306803)
86. Tarleton, R.L., Zhang, L. and Downs, M.O. (1997) "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proceedings of the National Academy of Sciences of the United States of America 94, 3932-3937
87. Tarleton, R.L. and Zhang, L. (1999) Chagas disease etiology: autoimmunity or parasite persistence? Parasitology Today 15, 94-99
88. Tarleton, R.L. (2003) Chagas disease: a role for autoimmunity? Trends in Parasitology 19, 447-451
89. Garcia, S. et al. (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49, 1521-1528 (Pubitemid 40463384)
90. Bustamante, J.M., Bixby, L.M. and Tarleton, R.L. (2008) Drug-induced cure drives conversion to a stable and protective CD+ T central memory response in chronic Chagas disease. Nature Medicine 14, 542-550 (Pubitemid 351655210)
91. Walton, M.I. and Workman, P. (1987) Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology 36, 887-896 (Pubitemid 17038036)
92. Montalto de Mecca, M., Diaz, E.G. and Castro, J.A. (2002) Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Toxicology Letters 136, 1-8 (Pubitemid 35279612)
93. Mecca, M.M. et al. (2008) Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects. Memorias do Instituto Oswaldo Cruz 103, 549-553
94. Raether, W. and Hanel, H. (2003) Nitroheterocyclic drugs with broad spectrum activity. Parasitology Research 90, S19-39 (Pubitemid 36831290)
95. Docampo, R. (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chemico-Biological Interactions 73, 1-27
96. Docampo, R. et al. (1981) Generation of free radicals induced by nifurtimox in mammalian tissues. Journal of Biological Chemistry 256, 10930-10933 (Pubitemid 12181579)
97. Viode, C. et al. (1999) Enzymatic reduction studies of nitroheterocycles. Biochemical Pharmacology 57, 549-557 (Pubitemid 29073333)
98. Henderson, G.B. et al. (1988) "Subversive"substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proceedings of the National Academy of Sciences of the United States of America 85, 5374-5378
99. Blumenstiel, K. et al. (1999) Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochemical Pharmacology 58, 1791-1799 (Pubitemid 29505420)
100. Boveris, A. et al. (1980) Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochemical Journal 188, 643-648
101. Fairlamb, A.H. and Cerami, A. (1992) Metabolism and functions of trypanothione in the Kinetoplastida. Annual Review of Microbiology 46, 695-729
102. Flohe, L., Hecht, H.J. and Steinert, P. (1999) Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radical Biology and Medicine 27, 966-984 (Pubitemid 29507470)
103. Wilkinson, S.R. et al. (2002) Trypanosoma cruzi expresses a plant-like ascorbate-dependent hemoperoxidase localized to the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America 99, 13453-13458 (Pubitemid 35215402)
104. Wilkinson, S.R. and Kelly, J.M. (2003) The role of glutathione peroxidases in trypanosomatids. Biological Chemistry 384, 517-525 (Pubitemid 36609168)
105. Irigoín, F. et al. (2008) Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification. Free Radical Biology and Medicine 45, 733-742
106. Prathalingham, S.R. et al. (2007) Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrobial Agents and Chemotherapy 51, 755-758 (Pubitemid 46185302)
107. Wilkinson, S.R. et al. (2000) Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi. Journal of Biological Chemistry 275, 8220-8225 (Pubitemid 30159739)
108. Wilkinson, S.R. et al. (2002) The Trypanosoma cruzi enzyme TcGPXI is a glycosomal peroxidase and can be linked to trypanothione reduction by glutathione or tryparedoxin. Journal of Biological Chemistry 277, 17062-17071 (Pubitemid 34967736)
109. Wilkinson, S.R. et al. (2002) TcGPXII, a glutathione-dependent Trypanosoma cruzi peroxidase with substrate specificity restricted to fatty acid and phospholipid hydroperoxides, is localized to the endoplasmic reticulum. Biochemical Journal 364, 787-794 (Pubitemid 34680855)
110. Wilkinson, S.R. et al. (2003) RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the bloodstream form of the African trypanosome. Journal of Biological Chemistry 278, 31640-13646
111. Wilkinson, S.R. et al. (2006) Functional characterisation of the iron superoxide dismutase gene repertoire in Trypanosoma brucei. Free Radical Biology and Medicine 40, 198-209 (Pubitemid 43069346)
112. Kelly, J.M. et al. (1993) Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. European Journal of Biochemistry 218, 29-37 (Pubitemid 23350357)
113. Peterson, F.J. et al. (1979) Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. Journal of Biological Chemistry 254, 4009-4014
114. Roldan, M.D. et al. (2008) Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiology Reviews 32, 474-500 (Pubitemid 351538747)
115. McCalla, D.R., Reuvers, A. and Kaiser, C. (1971) Breakage of bacterial DNA by nitrofuran derivatives. Cancer Research 31, 2184-2188
116. Streeter, A.J. and Hoener, B.A. (1988) Evidence for the involvement of a nitrenium ion in the covalent binding of nitrofurazone to DNA. Pharmaceutical Research 5, 434-436
117. Maya, J.D. et al. (1997) Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Molecular and Biochemical Parasitology 86, 101-106 (Pubitemid 27245980)
118. Kubata, B.K. et al. (2002) A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. Journal of Experimental Medicine 196, 1241-1251 (Pubitemid 35304189)
119. Wilkinson, S.R. et al. (2008)Amechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 105, 5022-5027 (Pubitemid 351738503)
120. Nozaki, T., Engel, J.C. and Dvorak, J.A. (1996) Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi. American Journal of Tropical Medicine and Hygiene 55, 111-117
121. Murta, S.M. and Romanha, A.J. (1998) In vivo selection of a population ofTrypanosomacruzi and clones resistant to benznidazole. Parasitology 116, 165-171 (Pubitemid 28048696)
122. Nogueira, F.B. et al. (2006) Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Tropica 100, 119-132 (Pubitemid 44821036)
123. Murta, S.M. et al. (2006) Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Molecular and Biochemical Parasitology 146, 151-162 (Pubitemid 43356356)
124. Murta, S.M. et al. (2008) Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Tropica 107, 59-65
125. Andrade, H.M. et al. (2008) Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. Journal of Proteome Research 7, 2357-2367
126. Rego, J.V. et al. (2008) Trypanosoma cruzi: characterisation of the gene encoding tyrosine aminotransferase in benznidazole-resistant and susceptible populations. Experimental Parasitology 118, 111-117 (Pubitemid 350299335)
127. Campos, F.M. et al. (2009) Characterization of a gene encoding alcohol dehydrogenase in benznidazole-susceptible and-resistant populations of Trypanosoma cruzi. Acta Tropica 111, 56-63
128. Nogueira, F.B. et al. (2009) Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Parasitology Research 104, 835-844
129. Portal, P. et al. (2008) Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi suggested role on drug resistance. Molecular and Biochemical Parasitology 160, 42-51 (Pubitemid 351699263)
130. El-Sayed, N.M. et al. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science 309, 404-409
131. Berriman, M. et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309, 416-422
132. Meissner, M., Agop-Nersesian, C. and Sullivan, W.J., Jr (2007) Molecular tools for analysis of gene function in parasitic microorganisms. Applied Microbiology and Biotechnology 75, 963-975 (Pubitemid 46944555)
133. Motyka, S.A. and Englund, P.T. (2004) RNA interference for analysis of gene function in trypanosomatids. Current Opinion in Microbiology 7, 362-368 (Pubitemid 39091120)
134. Furlong, S.T. (1989) Sterols of parasitic protozoa and helminths. Experimental Parasitology 68, 482-485
135. Buckner, F. et al. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America 100, 15149-15153 (Pubitemid 37518031)
136. Buckner, F.S. et al. (2003) Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Molecular and Biochemical Parasitology 132, 75-81 (Pubitemid 37352903)
137. Buckner, F.S. et al. (2001) Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrobial Agents and Chemotherapy 45, 1210-1205
138. Urbina, J.A. et al. (2002) Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Molecular and Biochemical Parasitology 125, 35-45 (Pubitemid 35449244)
139. Lepesheva, G.I. et al. (2007) Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chemistry and Biology 14, 1283-1293 (Pubitemid 350102245)
140. Chen, C.K. et al. (2009) Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit. PLoS Neglected Tropical Diseases 3, e372
141. Konkle, M.E. et al. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. Journal of Medicinal Chemistry 52, 2846-2853
142. Coppens, I. and Courtoy, P.J. (2000) The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annual Review of Microbiology 54, 129-156
143. Urbina, J.A. and Docampo, R. (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends in Parasitology 19, 495-501 (Pubitemid 37329658)
144. Roberts, C.W. et al. (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Molecular and Biochemical Parasitology 126, 129-142 (Pubitemid 36255612)
145. Urbina, J.A. (2009) Ergosterol biosynthesis and drug development for Chagas disease. Memorias do Instituto Oswaldo Cruz 104, 311-318
146. Hucke, O. et al. (2005) The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. Journal of Medicinal Chemistry 48, 5415-5418 (Pubitemid 41209239)
147. Suryadevara, P.K. et al. (2009) Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. Journal of Medicinal Chemistry 52, 3703-3715
148. Kraus, J.M. et al. (2009) Rational modification of a candidate cancer drug for use against Chagas disease. Journal of Medicinal Chemistry 52, 1639-1647
149. McKerrow, J.H. et al. (2009) Two approaches to discovering and developing new drugs for Chagas disease. Memorias do Instituto Oswaldo Cruz 104, 263-269
150. Molina, J. et al. (2000) In vivo activity of the bistriazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Journal of Antimicrobial Chemotherapy 46, 137-140 (Pubitemid 30466211)
151. Urbina, J.A. et al. (2003) Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. International Journal of Antimicrobial Agents 21, 39-48 (Pubitemid 36043973)
152. Urbina, J.A. et al. (1988) Synergistic effects of ketoconazole and SF-86327 on the proliferation of epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Annals of the New York Academy of Sciences 544, 357-358 (Pubitemid 19259338)
153. Gerpe, A. et al. (2008) Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorganic and Medicinal Chemistry 16, 569-577
154. Maldonado, R.A. et al. (1993) Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrobial Agents and Chemotherapy 37, 1353-1359 (Pubitemid 23166739)
155. Hinshaw, J.C. et al. (2003) Oxidosqualene cyclase inhibitors as antimicrobial agents. Journal of Medicinal Chemistry 46, 4240-4243 (Pubitemid 37153005)
156. Urbina, J.A. et al. (1995) Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Molecular and Biochemical Parasitology 73, 199-210
157. Urbina, J.A. et al. (1996) Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42, 294-307
158. Magaraci, F. et al. (2003) Azasterols as inhibitors of sterol
159. Lorente, S.O. et al. (2004) Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrobial Agents and Chemotherapy 48, 2937-2950 (Pubitemid 38989159)
160. Gros, L. et al. (2006) Evaluation of azasterols as anti-parasitics. Journal of Medicinal Chemistry 49, 6094-6103 (Pubitemid 44484953)
161. Gigante, F. et al. (2009) SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorganic and Medicinal Chemistry 17, 5950-5961
162. Gros, L. et al. (2006) New azasterols against Trypanosoma brucei: role of 24-sterol methyltransferase in inhibitor action. Antimicrobial Agents and Chemotherapy 50, 2595-2601 (Pubitemid 44198676)
163. Cazzulo, J.J. et al. (1989) Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Molecular and Biochemical Parasitology 33, 33-41 (Pubitemid 19044514)
164. Murta, A.C. et al. (1990) Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Molecular and Biochemical Parasitology 43, 27-38 (Pubitemid 20306265)
165. Eakin, A.E. et al. (1992) The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. Journal of Biological Chemistry 267, 7411-7420
166. Caffrey, C.R. et al. (2001) Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Molecular and Biochemical Parasitology 118, 61-73 (Pubitemid 33043821)
167. Lima, A.P. et al. (1994) Identification of new cysteine protease gene isoforms in Trypanosoma cruzi. Molecular and Biochemical Parasitology 67, 333-338 (Pubitemid 24330745)
168. Garcia, M.P. et al. (1998) Characterisation of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Molecular and Biochemical Parasitology 91, 263-272
169. Nobrega, O.T. et al. (1998) Cloning and sequencing of tccb, a gene encoding a Trypanosoma cruzi cathepsin B-like protease. Molecular and Biochemical Parasitology 97, 235-240 (Pubitemid 28558718)
170. Mackey, Z.B. et al. (2004) A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. Journal of Biological Chemistry 279, 48426-48433 (Pubitemid 39541000)
171. Caffrey, C.R. and Steverding, D. (2009) Kinetoplastid papain-like cysteine peptidases. Molecular and Biochemical Parasitology 167, 12-19
172. McKerrow, J.H., McGrath, M.E. and Engel, J.C. (1995) The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitology Today 11, 279-282
173. Engel, J.C. et al. (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. Journal of Experimental Medicine 188, 725-734 (Pubitemid 28387935)
174. Du, X. et al. (2000) Aryl ureas represent a new class of anti-trypanosomal agents. Chemistry and Biology 7, 733-742
175. Roush, W.R. et al. (2001) Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorganic and Medicinal Chemistry Letters 11, 2759-2762 (Pubitemid 32925311)
176. Du, X. et al. (2002) Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. Journal of Medicinal Chemistry 45, 2695-2707 (Pubitemid 34627642)
177. Greenbaum, D.C. et al. (2004) Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. Journal of Medicinal Chemistry 47, 3212-3219 (Pubitemid 38702713)
178. Nkemgu, N.J. et al. (2003) Improved trypanocidal activities of cathepsin L inhibitors. International Journal of Antimicrobial Agents 22, 155-1559
179. Doyle, P.S. et al. (2007)Acysteine protease inhibitor cures Chagas' disease in an immunodeficientmouse model of infection. Antimicrobial Agents and Chemotherapy 51, 3932-3939 (Pubitemid 350057791)
180. Chen, Y.T. et al. (2008) Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorganic and Medicinal Chemistry Letters 18, 5860-5863
181. Mallari, J.P. et al. (2008) Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters 18, 2883-2885 (Pubitemid 351608880)
182. Mallari, J.P. et al. (2008) Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. Journal of Medicinal Chemistry 51, 545-552 (Pubitemid 351252282)
183. McGrath, M.E. et al. (1995) The crystal structure of cruzain: a therapeutic target for Chagas' disease. Journal of Molecular Biology 247, 251-259
184. Eakin, A.E. et al. (1993) Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. Journal of Biological Chemistry 268, 6115-6118 (Pubitemid 23099296)
185. Huang, L., Brinen, L.S. and Ellman, J.A. (2003) Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Bioorganic and Medicinal Chemistry 11, 21-29 (Pubitemid 35430117)
186. Choe, Y. et al. (2005) Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorganic and Medicinal Chemistry 13, 2141-2156 (Pubitemid 40261134)
187. Kerr, I.D. et al. (2009)Vinyl sulfones as antiparasitic agents: A structural basis for drug design. Journal of Biological Chemistry 284, 25697-25703
188. Tomas, A.M., Miles, M.A. and Kelly, J.M. (1997) Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. European Journal of Biochemistry 244, 596-603 (Pubitemid 27110765)
189. Abdulla, M.H. et al. (2008) RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Neglected Tropical Diseases 2, e298
190. Krauth-Siegel, R.L. and Comini, M.A. (2008) Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochimica et Biophysica Acta 1780, 1236-1248
191. Krauth-Siegel, R.L. and Inhoff, O. (2003) Parasite-specific trypanothione reductase as a drug target molecule. Parasitology Research 90, S77-85 (Pubitemid 36831282)
192. Jaeger, T. and Flohe, L. (2006) The thiol-based redox networks of pathogens: unexploited targets in the search for new drugs. Biofactors 27, 109-120 (Pubitemid 44444593)
193. Comini, M.A., Krauth-Siegel, R.L. and Flohe, L. (2007) Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes. Biochemical Journal 402, 43-49
194. Comini, M.A. et al. (2004) Valdiation of Trypanosoma brucei trypanothione synthetase as drug target. Free Radical Biology and Medicine 36, 1289-1302 (Pubitemid 38526323)
195. Ariyanayagam, M.R. et al. (2005) Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochemical Journal 391, 425-432 (Pubitemid 41532441)
196. Wyllie, S. et al. (2009) Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Molecular Microbiology Jun 24; [Epub ahead of print]
197. Jockers-Scherubl, M.C., Schirmer, R.H. and Krauth-Siegel, R.L. (1989) Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds. European Journal of Biochemistry180, 267-272 (Pubitemid 19088813)
198. Fournet, A. et al. (1998) Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase. Journal of Enzyme Inhibition 13, 1-9 (Pubitemid 28154261)
199. Zani, C.L. et al. (1997) Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiopen-4,9-quinones. Bioorganic and Medicinal Chemistry 5, 2185-2192 (Pubitemid 28012606)
200. Bond, C.S. et al. (1999) Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure 7, 81-89 (Pubitemid 29159184)
201. Gallwitz, H. et al. (1999) Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. Journal of Medicinal Chemistry 42, 364-372 (Pubitemid 29085096)
202. Fournet, A. et al. (2000) Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model. International Journal of Antimicrobial Agents 13, 189-195
203. Salmon-Chemin, L. et al. (2000) Parallel synthesis of a library of 1,4-naphthoquinones and automated screening of potential inhibitors of trypanothione reductase from Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters 10, 631-635 (Pubitemid 30186666)
204. Salmon-Chemin, L. et al. (2001) 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. Journal of Medicinal Chemistry 44, 548-565 (Pubitemid 32156097)
205. Zani, C.L. and Fairlamb, A.H. (2003) 8-Methoxynaphtho[2,3-b]thiophen-4,9- quinone, a non-competitive inhibitor of trypanothione reductase. Memorias do Instituto Oswaldo Cruz 98, 565-568 (Pubitemid 38019624)
206. Hamilton, C.J. et al. (2003) Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochemical Journal 369, 529-537 (Pubitemid 36246236)
207. Hamilton, C.J. et al. (2003) Benzofuranyl 3,5-bispolyamine derivatives as time-dependent inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry 11, 3683-3693 (Pubitemid 36952267)
208. Hamilton, C.J. et al. (2006) Time-dependent inhibitors of trypanothione reductase: analogues of the spermidine alkaloid lunarine and related natural products. Bioorganic and Medicinal Chemistry 14, 2266-2278 (Pubitemid 43254739)
209. Stump, B. et al. (2007) Betraying the parasite's redox system: diaryl sulfide-based inhibitors of trypanothione reductase: subversive substrates and antitrypanosomal properties. ChemMedChem 2, 1708-1712
210. Martyn, D.C. et al. (2007) High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorganic and Medicinal Chemistry Letters 17, 1280-1283 (Pubitemid 46240853)
211. Czechowicz, J.A. et al. (2007) The synthesis and inhibitory activity of dethiotrypanothione and analogues against trypanothione reductase. Journal of Organic Chemistry 72, 3689-3693 (Pubitemid 46762451)
212. Stump, B. et al. (2009) Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines. Chembiochem 10, 79-83
213. Stump, B. et al. (2008) Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities. Organic and Biomolecular Chemistry 6, 3935-3947
214. Holloway, G.A. et al. (2009) Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrobial Agents and Chemotherapy 53, 2824-2833
215. Holloway, G.A. et al. (2007) Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorganic and Medicinal Chemistry Letters 17, 1422-1427
216. Cavalli, A. et al. (2009) Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry Letters 19, 3031-3035
217. Richardson, J.L. et al. (2009) Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. ChemMedChem 4, 1333-1340
218. Patterson, S. et al. (2009) Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl) piperidine (BTCP) analogues as inhibitors of trypanothione reductase. ChemMedChem 4, 1341-1353
219. Zhang, Y. et al. (1993) Trypanosoma cruzi trypanothione reductase. Crystallization, unit cell dimensions and structure solution. Journal of Molecular Biology 232, 1217-1220 (Pubitemid 23276435)
220. Lantwin, C.B. et al. (1994) The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state. Proteins 18, 161-173 (Pubitemid 24055078)
221. Jacoby, E.M. et al. (1996) Crystal structure of the Trypanosoma cruzi trypanothione reductase.mepacrine complex. Proteins 24, 73-80 (Pubitemid 26044596)
222. Zhang, Y. et al. (1996) The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. Protein Science 5, 52-61
223. Saravanamuthu, A. et al. (2004) Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. Journal of Biological Chemistry 279, 29493-29500 (Pubitemid 38915829)
224. Meiering, S. et al. (2005) Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. Journal of Medicinal Chemistry 48, 4793-4802 (Pubitemid 41033122)
225. Ogungbe, I.V. and Setzer,W.N. (2009)Comparative molecular docking of antitrypanosomal natural products into multiple Trypanosoma brucei drug targets. Molecules 14, 1513-1536
226. Alphey, M.S. et al. (2003) Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei: photoreduction of the redox disulfide using synchrotron radiation and evidence for a conformational switch implicated in function. Journal of Biological Chemistry 278, 25919-25925 (Pubitemid 36835354)
227. Alphey, M.S., Konig, J. and Fairlamb, A.H. (2008) Structural and mechanistic insights into type II trypanosomatid tryparedoxin-dependent peroxidases. Biochemical Journal 414, 375-381
228. Melchers, J. et al. (2008) Structural basis for a distinct catalytic mechanism in Trypanosoma brucei tryparedoxin peroxidase. Journal of Biological Chemistry 283, 30401-30411
229. Bitonti, A.J., Kelly, S.E. and McCann, P.P. (1984) Characterization of spermidine synthase from Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 13, 21-28 (Pubitemid 14024944)
230. Tekwani, B.L., Bacchi, C.J. and Pegg, A.E. (1992) Putrescine activated S-adenosylmethionine decarboxylase from Trypanosoma brucei brucei. Molecular and Cellular Biochemistry 117, 53-61
231. Yarlett, N. et al. (1993) S-adenosylmethionine synthetase in bloodstream Trypanosoma brucei. Biochimica et Biophysica Acta 1181, 68-76 (Pubitemid 23087524)
232. Taylor, M.C. et al. (2008) Validation of spermidine synthase as a drug target in African trypanosomes. Biochemical Journal 409, 563-569 (Pubitemid 351184975)
233. Huynh, T.T. et al. (2003) Gene knockdown of gamma-glutamylcysteine synthetase by RNAi in the parasitic protozoa Trypanosoma brucei demonstrates that it is an essential enzyme. Journal of Biological Chemistry 278, 39794-39800 (Pubitemid 37248541)
234. Xiao, Y., McCloskey, D.E. and Phillips, M.A. (2009) RNA interference-mediated silencing of ornithine decarboxylase and spermidine synthase genes in Trypanosoma brucei provides insight into regulation of polyamine biosynthesis. Eukaryotic Cell 8, 747-755
235. Tekwani, B.L. et al. (1992) Irreversible inhibition of S-adenosylmethionine decarboxylase of Trypanosoma brucei brucei by S-adenosylmethionine analogues. Biochemical Pharmacology 44, 905-911
236. Guo, J. et al. (1995) S-(5′-deoxy-5′-adenosyl)-1-aminoxy-4- (methylsulfonio)-2-cyclopentene (AdoMao): an irreversible inhibitor of S-adenosylmethionine decarboxylase with potent in vitro antitrypanosomal activity. Journal of Medicinal Chemistry 38, 1770-1777
237. Brun, R. et al. (1996) In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrobial Agents and Chemotherapy 40, 1442-1447
238. Marasco, C.J., Jr et al. (2002) Synthesis and evaluation of analogues of 5′-([(Z)-4-amino-2-butenyl]methylamino)-5′-deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity. Journal of Medicinal Chemistry 45, 5112-5122
239. Hirth, B. et al. (2009) Discovery of new S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis (HAT). Bioorganic and Medicinal Chemistry Letters 19, 2916-2919
240. Bitonti, A.J. et al. (1990) Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrobial Agents and Chemotherapy 34, 1485-1490 (Pubitemid 20257593)
241. Bacchi, C.J. et al. (1992) Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrobial Agents and Chemotherapy 36, 2736-2740
242. Bacchi, C.J. et al. (1996) In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrobial Agents and Chemotherapy 40, 1448-1453 (Pubitemid 26170000)
243. Byers, T.L. et al. (1991) Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine. Biochemical Journal 274, 527-533
244. Bacchi, C.J. et al. (2009) Trypanocidal activity of 8-methyl-5′- {[(Z)-4-aminobut-2-enyl]-(methylamino)} adenosine (Genz-644131), an adenosylmethionine decarboxylase inhibitor. Antimicrobial Agents and Chemotherapy 53, 3269-3272
245. Barker, R.H., Jr et al. (2009) Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrobial Agents and Chemotherapy 53, 2052-2058
246. Priotto, G. et al. (2007) Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clinical Infectious Disease 45, 1435-1442 (Pubitemid 351411872)
247. Rane, L., Rane, D. and Kinnamon, K.E. (1976) Screening large numbers of compounds in a model based on mortality of Trypanosoma rhodesiense infected mice. American Journal of Tropical Medicine and Hygiene 25, 395-400
248. Das, B.P. and Boykin, D.W. (1977) Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. Journal of Medicinal Chemistry 20, 531-536
249. Ansede, J.H. et al. (2005) In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica 35, 211-226 (Pubitemid 40776556)
250. Conte, J.E., Jr et al. (1986) Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. Journal of Infectious Diseases 154, 923-929
251. Burri, C. and Brun, R. (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitology Research 90, S49-52 (Pubitemid 36831292)
252. Paulos, C. et al. (1989) Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology 27, 454-457 (Pubitemid 19225360)
253. Raaflaub, J. and Ziegler, W.H. (1979) Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 29, 1611-1614 (Pubitemid 10231718)